AU2020359291B2 - Medicinal cognitive treatments - Google Patents

Medicinal cognitive treatments

Info

Publication number
AU2020359291B2
AU2020359291B2 AU2020359291A AU2020359291A AU2020359291B2 AU 2020359291 B2 AU2020359291 B2 AU 2020359291B2 AU 2020359291 A AU2020359291 A AU 2020359291A AU 2020359291 A AU2020359291 A AU 2020359291A AU 2020359291 B2 AU2020359291 B2 AU 2020359291B2
Authority
AU
Australia
Prior art keywords
baseline
score
xanamem
treatment group
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020359291A
Other languages
English (en)
Other versions
AU2020359291A1 (en
Inventor
John William KETELBEY
Tamara Diane MILLER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Actinogen Medical Ltd
Original Assignee
Actinogen Medical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2019903681A external-priority patent/AU2019903681A0/en
Application filed by Actinogen Medical Ltd filed Critical Actinogen Medical Ltd
Publication of AU2020359291A1 publication Critical patent/AU2020359291A1/en
Application granted granted Critical
Publication of AU2020359291B2 publication Critical patent/AU2020359291B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2020359291A 2019-09-30 2020-09-30 Medicinal cognitive treatments Active AU2020359291B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2019903681 2019-09-30
AU2019903681A AU2019903681A0 (en) 2019-09-30 Medicinal cognitive treatments
PCT/AU2020/051043 WO2021062472A1 (en) 2019-09-30 2020-09-30 Medicinal cognitive treatments

Publications (2)

Publication Number Publication Date
AU2020359291A1 AU2020359291A1 (en) 2022-04-21
AU2020359291B2 true AU2020359291B2 (en) 2026-04-30

Family

ID=75336310

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020359291A Active AU2020359291B2 (en) 2019-09-30 2020-09-30 Medicinal cognitive treatments

Country Status (11)

Country Link
US (1) US20230000843A1 (enExample)
EP (1) EP4037684A4 (enExample)
JP (1) JP2022550221A (enExample)
KR (1) KR20220080116A (enExample)
CN (1) CN114761005A (enExample)
AU (1) AU2020359291B2 (enExample)
CA (1) CA3152902A1 (enExample)
CL (1) CL2022000781A1 (enExample)
IL (1) IL292739B2 (enExample)
MX (1) MX2022003845A (enExample)
WO (1) WO2021062472A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI855081B (zh) * 2019-05-24 2024-09-11 美商賽吉醫療公司 化合物、組合物及使用方法
IL303170A (en) * 2020-11-25 2023-07-01 Sage Therapeutics Inc 4-fluoro-(4-(4-benzyl)piperidin-1-yl)(2-(pyrimidin-4-yl)pyridin-3-yl)methanone derivatives and similar compounds as cyp46a1 inhibitors for the treatment of neurodegenerative disorders
WO2024073794A1 (en) * 2022-10-07 2024-04-11 Actinogen Medical Limited SUBJECT SELECTION FOR 11β-HSD1 INHIBITOR TREATMENT
CN121969372A (zh) * 2023-10-03 2026-05-01 射线质医疗有限公司 片剂制剂

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011033255A1 (en) * 2009-09-16 2011-03-24 The University Of Edinburgh (4-phenyl-piperidin-1-yl)-[5-1h-pyrazol-4yl)-thiophen-3-yl]-methanone compounds and their use
WO2011135276A1 (en) * 2010-04-29 2011-11-03 The University Of Edinburgh 3, 3 -disubstituted- ( 8 - aza - bicyclo [3.2.1] oct- 8 - yl) -[5- (1h - pyrazol - 4 -yl) -thiophen-3 -yl] methanones as inhibitors of 11 (beta) -hsd1

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011033255A1 (en) * 2009-09-16 2011-03-24 The University Of Edinburgh (4-phenyl-piperidin-1-yl)-[5-1h-pyrazol-4yl)-thiophen-3-yl]-methanone compounds and their use
WO2011135276A1 (en) * 2010-04-29 2011-11-03 The University Of Edinburgh 3, 3 -disubstituted- ( 8 - aza - bicyclo [3.2.1] oct- 8 - yl) -[5- (1h - pyrazol - 4 -yl) -thiophen-3 -yl] methanones as inhibitors of 11 (beta) -hsd1

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "XanamemTM in Healthy Elderly Subjects (XanaHES)", CLINICALTRIALS.GOV, 3 February 2019 (2019-02-03), pages 1 - 8, XP055915357, Retrieved from the Internet <URL:https://clinicaltrials.gov/ct2/history/NCT03830762?V_1=View#StudyPageTop> [retrieved on 20220426] *
KAREN CHAPMAN, MEGAN HOLMES, JONATHAN SECKL: "11β-Hydroxysteroid Dehydrogenases: Intracellular Gate-Keepers of Tissue Glucocorticoid Action", PHYSIOLOGICAL REVIEWS, AMERICAN PHYSIOLOGICAL SOCIETY, US, vol. 93, no. 3, 1 July 2013 (2013-07-01), US, pages 1139 - 1206, XP055762364, ISSN: 0031-9333, DOI: 10.1152/physrev.00020.2012 *
MACLULLICH ALASDAIR M.J., FERGUSON KAREN J., REID LOUISE M., DEARY IAN J., STARR JOHN M., WARDLAW JOANNA M., WALKER BRIAN R., ANDR: "11β-hydroxysteroid dehydrogenase type 1, brain atrophy and cognitive decline", NEUROBIOLOGY OF AGING, TARRYTOWN, NY, US, vol. 33, no. 1, 1 January 2012 (2012-01-01), US, pages 207.e1 - 207.e8, XP055812187, ISSN: 0197-4580, DOI: 10.1016/j.neurobiolaging.2010.09.010 *
SANDEEP T. C., YAU J. L. W., MACLULLICH A. M. J., NOBLE J., DEARY I. J., WALKER B. R., SECKL J. R.: "11 -Hydroxysteroid dehydrogenase inhibition improves cognitive function in healthy elderly men and type 2 diabetics", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES (PNAS), NATIONAL ACADEMY OF SCIENCES, vol. 101, no. 17, 27 April 2004 (2004-04-27), pages 6734 - 6739, XP055812184, ISSN: 0027-8424, DOI: 10.1073/pnas.0306996101 *
SOOY, K. ET AL.: "Cognitive and Disease-Modifying Effects of 1 Ibeta-Hydroxysteroid Dehydrogenase Type 1 Inhibition in Male Tg2576 Mice, a Model of Alzheimer's Disease", ENDO CRINOLOGY, vol. 156, no. 12, (2015-12-01), pages 4592 - 603 *
SOOY, K. ET AL.: "Partial deficiency or short-term inhibition of 1 1 P-hydroxysteroid dehydrogenase type 1 improves cognitive function in aging mice", J NEUROSCI, vol. 30, no. 41, 13 October 2010 (2010-10-13), pages 13867 - 72, *
WEBSTER, SP. ET AL.: "Selection and early clinical evaluation of the brain-penetrant 11beta- hydroxysteroid dehydrogenase type 1 (11beta-HSDl) inhibitor UE2343 (XanamemTM", BR J PHARMACOL ., vol. 174, no. 5, (2017-03-01), pages 396 - 408 *

Also Published As

Publication number Publication date
CL2022000781A1 (es) 2022-11-18
CN114761005A (zh) 2022-07-15
WO2021062472A1 (en) 2021-04-08
US20230000843A1 (en) 2023-01-05
KR20220080116A (ko) 2022-06-14
JP2022550221A (ja) 2022-11-30
AU2020359291A1 (en) 2022-04-21
EP4037684A1 (en) 2022-08-10
MX2022003845A (es) 2022-06-22
CA3152902A1 (en) 2021-04-08
IL292739B2 (en) 2026-08-01
IL292739B1 (en) 2026-04-01
EP4037684A4 (en) 2023-11-01
IL292739A (en) 2022-07-01

Similar Documents

Publication Publication Date Title
US20210169964A1 (en) Methods of treating alzheimer&#39;s disease, huntington&#39;s disease, autism, and other disorders
US20230000843A1 (en) Medicinal cognitive treatments
KR20150003765A (ko) 라퀴니모드와 디메틸 푸마레이트의 병용물에 의한 다발성 경화증의 치료
EP3862000B1 (en) Medicine for treating chronic cough
TWI549678B (zh) ４－胺基吡啶於改善具有脫髓鞘及其他神經系統狀況之患者的神經認知及／或神經精神缺陷之用途
KR20230018384A (ko) T-형 칼슘 채널 조정제의 사용 방법
JP2024059863A (ja) リソソーム蓄積障害に関する医薬組成物及び使用
US20240358729A1 (en) Composition containing 2&#39;-fl for ameliorating, preventing or treating diseases caused by reduction of dopamine
US20250295646A1 (en) Methods of use of t-type calcium channel modulators
EP4531850A1 (en) Compounds for use in the treatment of diseases and conditions associated with neurodegenerative dysfunction
KR20190017873A (ko) 홀수의 탄소 원자를 갖는 지질 및 제약 조성물 또는 영양 보충제로서의 그의 용도
Kostadinova et al. 4-aminopyridine–the new old drug for the treatment of neurodegenerative diseases
TW201408300A (zh) 以拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）及氨吡啶（ｆａｍｐｒｉｄｉｎｅ）之組合治療多發性硬化症
GB2619119A (en) Compounds for use in the treatment of diseases and conditions associated with neurodegenerative dysfunction
AU2018260535B2 (en) Small organic molecules for use in the treatment of neuroinflammatory disorders
US20230330074A1 (en) Compounds and methods for treating spasticity
JP7744419B2 (ja) レット症候群を治療するためのプリドピジンまたはその類似体の使用
WO2012154710A1 (en) Treatment of cognitive disorders with certain alpha-7 nicotinic acid receptor agonists in combination with nicotine
CN120153257A (zh) 用于11β-HSD1抑制剂治疗的受试者选择
CA3257705A1 (en) TREATMENT OF PATIENTS RESISTANT TO ANTIDEPRESSANTS
HK40128287A (en) Methods of switching neuropsychiatric medications using ulotaront
JPWO2002010167A1 (ja) ２−アリール−８−オキソジヒドロプリン誘導体を有効成分とする痴呆症治療剤